Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men

Abstract

Objectives: To assess safety, tolerability, pharmacokinetics and hemodynamic effects of oral CF101, an A3 adenosine receptor (A3AR) agonist, in healthy men. Methods: One single and 1 repeated dose, parallel-group, ascending dose, double-blind and placebo-controlled study in normal volunteers. In the single dose study, n = 15 subjects received 1, 5 or 10 mg oral CF101; in each group 1 subject received placebo, the remainder active CF101. In the repeat-dose study, n = 28 subjects received repeated 12hourly oral doses of CF101 (2, 3, 4 or 5 mg) for 7 days, in each group 2 subjects received placebo, the remainder active CF101. Test materials: Single-dose study: CF101 in 30% Cremophor RH40. Multiple-dose study: CF101 in 0.5% methylcellulose suspension. Both studies: the corresponding vehicles were used as placebos. Galenicals were prepared remotely from the clinical study site to ensure double-blind nature of the study. Results tolerability: Single doses up to 5 mg CF101 were safe and well-tolerated. However, the single dose of 10 mg CF101 was associated with flushing, tachycardia, nausea and vomiting, which were viewed as doselimiting in normal volunteers. Single doses of CF101 (as well as the first of the multiple doses) were associated with increases in heart rate (8-24 beats/min after 5 mg and 18-55 beats/min after 10 mg). Multiple doses up to 4 mg 12-hourly for 7 days were safe and welltolerated. However, the 5 mg multiple-dose group reported headache, drowsiness, hot flushes and dizziness on standing; this declined with dosing duration and was not dose-limiting in this study. Adverse events were commonest near t max. Results pharmacokinetics: For oral CF101, the t max was always 1-2 h post-dose and t 1/2 about 9 h, in both the single-and multiple-dose studies. For a single 5 mg dose (mean ± SD) C max = 81.6 ± 23.6 ng/ml in the single dose study, and 63.6 ± 22.0 ng/ml after the first of the multiple doses; AUC inf was 904.0 ± 221.9 ng.h/ml and 596.1 ± 196.6 ng.h/ml for the 2 studies, respectively. After 7 days of multiple dosing there was little change, and AUC 0-24h = 601.0 ± 163.6 ng.h/ml. These pharmacokinetic parameters were linearly proportional to dose in the other treatment groups. Results pharmacodynamics: Increases in heart rate were related to plasma concentration and evident only in the upper range of concentrations observed. There were no changes on ECG monitoring beyond sinus tachycardia, and, in particular, no evidence of PR prolongation in any subject (n = 43). In comparison with single doses, this response was almost absent after 7 days of dosing. Leucocytosis (increases up to about 1.5 × 10 9 /l after 5 and 10 mg) was similarly transient and reversible after multiple dosing. Conclusions: Single oral doses up to 5 mg CF101 and repeated doses up to 4 mg 12-hourly for 7 days were safe and welltolerated. Multiple-dose CF101 pharmacokinetics were unchanged and predictable from single-dose estimates, and were linearly proportional to dose. Increases in heart rate and neutrophil count were reversible du...

The A3Adenosine Receptor: History and Perspectives

“…Oral treatment with CF101 has led to amelioration and a marked decrease in clinical manifestations of the disease. In a phase I study in healthy subjects, CF101 proved safe and well tolerated, offering linear pharmacokinetic activity (van Troostenburg et al, 2004). This was confirmed in a now successfully concluded phase II study in RA patients in which CF101 mediated improvement in signs and symptoms, thus suggesting an opportunity for its development as an antirheumatic agent (Silverman et al, 2008;ClinicalTrials.gov).…”

Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease

“…[45] Adenosine agonists in humans may be limited by dose related adverse effects: flushing, tachycardia, nausea, vomiting, and leukocytosis have been reported. [46] This agent has not been studied in CKD.…”

Activation of adenosine low-affinity A3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine

“…An adenosine kinase inhibitor (26,54) or the A3 agonist IB-MECA (43) may be beneficial in murine models of colitis or a rat 2,4,6-trinitrobenzenesulfonic acid-induced colitis model (37), but the mechanisms involved remain poorly understood. IB-MECA is well tolerated orally by healthy human volunteers (63) and has been in Phase II clinical trials for another chronic inflammatory disease, rheumatoid arthritis, and is apparently without toxicity (www.canfite.com/develop.html).…”